Idorsia's selatogrel hits goals in phase 2 cardiovascular trials by Nick Paul Taylor Tuesday, December 18, 2018 The primary endpoint successes in patients with stable CAD or AMI set Idorsia up to plan the initiation of a phase 3 study.
Idorsia sheds surplus DMD therapy to Santhera by Phil Taylor Wednesday, November 21, 2018 Santhera plans $50 million placement to fund the purchase of a license to ReveraGen’s Duchene muscular dystrophy drug vamorolone from Idorsia.
Sage expands into sleep disorders after early-phase success by Nick Paul Taylor Wednesday, January 31, 2018 Sage committed to initiating sleep disorder trials of the GABA receptor modulator after getting a look at data from a study in healthy volunteers.
